alendronate has been researched along with Anemia, Cooley's in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | 3.01 | Treatment for osteoporosis in people with beta-thalassaemia. ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| " Clodronate treatment at our dosage is ineffective in this pathology in spite of the good compliance of patients." | 2.70 | Bisphosphonates in the treatment of thalassemia-induced osteoporosis. ( Crisafulli, A; Di Pietro, C; Frisina, N; Gaudio, A; Lasco, A; Meo, A; Morabito, N, 2002) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture." | 2.53 | Treatment for osteoporosis in people with ß-thalassaemia. ( Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, A | 2 |
| Swe, KMM | 1 |
| Sinha, NK | 2 |
| Chatterjee, R | 1 |
| Bajoria, R | 1 |
| Shah, FT | 1 |
| Porter, JB | 1 |
| Fedele, S | 1 |
| Tournis, S | 1 |
| Dede, AD | 1 |
| Savvidis, C | 1 |
| Triantafyllopoulos, IK | 1 |
| Kattamis, A | 1 |
| Papaioannou, N | 1 |
| Swe, KM | 1 |
| Osunkwo, I | 1 |
| Skordis, N | 1 |
| Ioannou, YS | 1 |
| Kyriakou, A | 1 |
| Savva, SC | 1 |
| Efstathiou, E | 1 |
| Savvides, I | 1 |
| Christou, S | 1 |
| Gaudio, A | 2 |
| Morabito, N | 2 |
| Xourafa, A | 1 |
| Currò, M | 1 |
| Caccamo, D | 1 |
| Ferlazzo, N | 1 |
| Macrì, I | 1 |
| La Rosa, MA | 1 |
| Meo, A | 2 |
| Ientile, R | 1 |
| Lasco, A | 1 |
| Crisafulli, A | 1 |
| Di Pietro, C | 1 |
| Frisina, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis[NCT03040765] | Phase 3 | 17 participants (Actual) | Interventional | 2018-05-14 | Terminated (stopped due to failed to recruit eligible subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alendronate and Anemia, Cooley's
| Article | Year |
|---|---|
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Frac | 2023 |
Treatment for osteoporosis in people with ß-thalassaemia.
Topics: Adolescent; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Ch | 2016 |
2 trials available for alendronate and Anemia, Cooley's
| Article | Year |
|---|---|
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Topics: Absorptiometry, Photon; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservatio | 2008 |
Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Analysis of Variance; beta-Thalassemia; Biom | 2002 |
3 other studies available for alendronate and Anemia, Cooley's
| Article | Year |
|---|---|
High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major.
Topics: Alendronate; beta-Thalassemia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Cons | 2014 |
Effects of teriparatide retreatment in a patient with β-thalassemia major.
Topics: Adult; Alendronate; beta-Thalassemia; Bone Density Conservation Agents; Bone Diseases; Humans; Male; | 2015 |
Role of genetic pattern on bone mineral density in thalassemic patients.
Topics: Adult; Alendronate; beta-Thalassemia; Bone Density; Female; Humans; Male; Polymorphism, Genetic | 2010 |